Related Experiment Videos
[Brain metastases of malignant melanomas]
C Boaziz1, J L Breau, J F Morere
1Service d'oncologie médicale, hôpital Avicenne, Bobigny, France.
Bulletin Du Cancer
|January 1, 1991
Summary
Malignant melanoma brain metastases have a poor prognosis. Fotemustine, a novel nitrosourea, shows promise with a 28.2% response rate, potentially improving survival for these patients.
Area of Science:
- Oncology
- Neuro-oncology
- Pharmacology
Context:
- Cerebral metastases from malignant melanoma are associated with a poor prognosis.
- Current treatments like surgery, chemotherapy (Dacarbazine), and biological response modifiers (Interleukin 2) have limitations in treating brain metastases.
- Existing nitrosoureas (BCNU, CCNU) show limited efficacy due to poor blood-brain barrier penetration.
Purpose:
- To evaluate the efficacy of fotemustine (muphoran), a new nitrosourea derivative, in patients with cerebral melanoma metastases.
- To assess the response rate and survival impact of fotemustine in this patient population.
Summary:
- Fotemustine, an amino acid-linked nitrosourea, demonstrated a response rate of up to 28.2% in patients with cerebral melanoma metastases.
- Unlike other agents, fotemustine can cross the blood-brain barrier, offering a therapeutic advantage.
- Responding patients showed a significant increase in survival.
Impact:
- Fotemustine represents a promising therapeutic option for malignant melanoma with brain metastases.
- Its availability may lead to combination therapies with surgery and radiotherapy to enhance patient survival.
- Further research into fotemustine's role in multimodal treatment strategies is warranted.